– UK, Oxford – Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive Director of the Group.

Mr. Soland was previously Senior Vice President and Chief Operating Officer of ViroPharma from 2008 until its acquisition by Shire in 2014. Prior to this he served as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his time at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States.

Prior to this, Mr. Soland was President at Chiron Vaccines from 2005 to 2006. During this time he oversaw the growth of the vaccine business to more than $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals.

Mr. Soland began his career at GlaxoSmithKline in 1993, occupying a number of roles including Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of Tarsa Therapeutics, DBV Technologies SA., and ACADIA Pharmaceuticals.

John Dawson, CEO of Oxford BioMedica, commented: “Daniel is a highly experienced biopharmaceutical executive with an outstanding track-record of leadership and innovation. As we continue to focus on driving our business forward, his knowledge of the US environment and extensive experience of clinical development and launching of new drugs will prove invaluable. In addition, his experience in leading manufacturing and quality organisations is highly relevant as we look to continue expansion of our already successful OXB Solutions business. He is an excellent fit for Oxford BioMedica and we look forward to him joining our Board.”

Mr Soland’s appointment will commence with immediate effect.

AboutOxford BioMedica plc

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group’s industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>

Comments are closed.